NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H2 2018
Summary
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2
- Introduction
- Global Markets Direct Report Coverage
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Overview
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Companies Involved in Therapeutics Development
- GlaxoSmithKline Plc
- Jyant Technologies Inc
- NuSirt Biopharma Inc
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Drug Profiles
- (acamprosate + ribavirin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (leucine + metformin hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (leucine + sildenafil citrate) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- resveratrol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- resveratrol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SRT-3025 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- toxoflavin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Dormant Products
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Discontinued Products
- NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Product Development Milestones
- Featured News & Press Releases
- Jun 10, 2016: NuSirt Biopharma Presenting New Research at American Diabetes Association's 76th Annual Scientific Sessions
- Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions
- May 18, 2016: NuSirt Biopharma to Present at American Diabetes Association's 76th Scientific Sessions
- Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes
- Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
- Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
- Jun 25, 2015: New Study: NuSirt Technology Demonstrates Potential as New Type 2 Diabetes Therapy
- Jun 06, 2015: NuSirt Biopharma Presenting New Data On Leucine-Metformin Combination at American Diabetes Association 75th Scientific Sessions
- Jul 18, 2014: Nashville-based pharmaceutical company readies for human trials
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Indication, H2 2018
- Number of Products under Development by Companies, H2 2018
- Products under Development by Companies, H2 2018
- Number of Products under Investigation by Universities/Institutes, H2 2018
- Products under Investigation by Universities/Institutes, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Stage and Route of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
- Pipeline by GlaxoSmithKline Plc, H2 2018
- Pipeline by Jyant Technologies Inc, H2 2018
- Pipeline by NuSirt Biopharma Inc, H2 2018
- Dormant Products, H2 2018
- Dormant Products, H2 2018 (Contd..1), H2 2018
- Discontinued Products, H2 2018
- List of Figures
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Top 10 Indications, H2 2018
- Number of Products by Mechanism of Actions, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Routes of Administration, H2 2018
- Number of Products by Stage and Routes of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook